Regulatory Updates
Sep 21, 2026•1 min read
Il-yang Pharma Ends Russian Deal for CML Drug Suphect, Shifts Focus to China
Il-yang Pharmaceutical terminated its supply and technology export agreement with Russia's R‑Pharm for the domestic new drug Suphect (radotinib) after no local trials, while pursuing Chinese approval.
Regulatory Updates
Sep 3, 2026•1 min read
China’s Fast‑Follower Model Pressures Biotech IP Strategies
Intensifying global drug development competition highlights the need for strong patents, timed disclosures and strategic workarounds as China’s fast‑follower biotech sector accelerates patient recruitment and cuts clinical costs.
1
Regulatory Updates
Sep 1, 2026•1 min read
China NHSA uncovers signature fraud by foreign innovator in VBP bid
China's NHSA revealed that a foreign innovative pharma company falsified over 80% of doctor signatures in a price‑bid petition, prompting warnings amid VBP expansion.
1